$GILD Headlines Trade what you see, not what y
Post# of 144503
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt
Gilead Sciences Is Not Done Running 10:04 a.m. Today - Seeking Alpha
Biotechnology, Oil And Brazil ETFs To Watch This Week 9:05 a.m. Today - Benzinga.com
Ambit Biosciences (AMBI) Jumps: Stock Up 6.6% - Tale of the Tape 9:04 a.m. Today - Zacks.com
Mike Khouw's Gilead Sciences Trade 10:20 a.m. Aug. 30, 2014 - benzinga.com
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog 6:30 p.m. Aug. 29, 2014 - Zacks.com
Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog 6:10 p.m. Aug. 29, 2014 - Zacks.com
Intellipharmaceutics' Oxycodone Program to Prevent Overdose - Analyst Blog 5:10 p.m. Aug. 29, 2014 - Zacks.com
Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog 5:00 p.m. Aug. 29, 2014 - Zacks.com
Isis Pharmaceuticals Starts Phase III Study on ISIS-APOCIIIRx - Analyst Blog 4:55 p.m. Aug. 29, 2014 - Zacks.com
Momenta-Sandoz's Generic Copaxone Accepted for Review by FDA - Analyst Blog 3:20 p.m. Aug. 29, 2014 - Zacks.com
What You Need to Know About the Roche-InterMune Deal 2:51 p.m. Aug. 29, 2014 - benzinga.com
4 Biotechs That Might Be Bought Soon 10:53 a.m. Aug. 29, 2014 - Investors Business Daily
Market Posts Best August In 14 Years. Why Don't Investors Feel Better? 10:30 a.m. Aug. 29, 2014 - Seeking Alpha
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale of the Tape 9:11 a.m. Aug. 29, 2014 - Zacks.com
Why Gilead Sciences (GILD) Could Be Positioned for a Surge? - Tale of the Tape 8:53 a.m. Aug. 29, 2014 - Zacks.com
OncoMed Pharmaceuticals (OMED) in Focus: Stock Up 9.9% - Tale of the Tape 8:51 a.m. Aug. 29, 2014 - Zacks.com
Today's Market: Red Hot Biotech And Big Pharma Names To Watch 8:22 a.m. Aug. 29, 2014 - Seeking Alpha
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog 6:50 p.m. Aug. 28, 2014 - Zacks.com
RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog 6:40 p.m. Aug. 28, 2014 - Zacks.com
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog 6:20 p.m. Aug. 28, 2014 - Zacks.com
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX